Orshe

Two GSK execs were asked to quit the nonprofit’s board after the drug maker learned it was selling resveratrol supplements.

See the rest here: GlaxoSmithKline Tells Execs to Leave Nonprofit Selling Resveratrol Supplements

Aetna Chairman and CEO Ronald Williams discusses the recent partnership between Aetna and CVS Caremark in an interview with WSJ Deputy Managing Editor Alan Murray.

See more here:  Aetna CEO: CVS Partnership Good for Shareholders/a>

What’s responsible for the age-related performance declines seen in most sports?

See more here: What Does Aging Mean for Elite Athletes? (Lance, We Mean You)

Bayer and GE are also developing diagnostic compounds to be used in tandem with imaging.

Here is the original:  Study: Avid’s Imaging Dye Can Detect Alzheimer’s From Scan

Until this month, there wasn’t much solid evidence that HGH improves aspects of athletic performance.

Read more:  Does Human Growth Hormone Actually Do Anything for Athletes?

Skin types at the fair end of the spectrum are more susceptible to the burning rays of the sun — and to a higher risk for cancers and premature aging of the skin. But a little sun exposure also releases endorphins and gives us needed vitamin D. WSJ’s Melinda Beck and Laura Landro debate how good or bad the sun is for you on the News Hub.

Read the original post:  News Hub: The Sun and Your Health/a>

A few items of interest involving the FDA:

Congress last year added the tobacco industry to the FDA’s regulatory mix and today a panel of health experts making up the agency’s new Tobacco Products Scientific Advisory Committee is kicking off a two-day meeting. First on the agenda: how menthol flavoring in cigarettes affects smokers’ habits.

Consumer demand for innovation and customization, a boon for new entrants such as Beachbody and CrossFit, could spur capital markets activity in the sector, says Joe Pellegrini, managing director of Robert W. Baird’s consumer investment banking group.

Read more from the original source: Content Spurs Changes In U.S. Fitness Sector/a>

A nationwide push is underway to lower radiation exposure from CT scans, amid growing concern about the risks of cancer linked to the high-powered imaging technology, as I write in the Informed Patient column today.

Last we heard of Fablyn, an experimental bone drug for the treatment of postmenopausal women, U.S. regulators were holding off on approval after FDA staff and outside reviewers raised concerns and Pfizer, the pill’s maker, was shopping it around to other companies.